# NCT06034002 (NCT06034002)

> A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06034002
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Myeloproliferative Neoplasms
- Interventions: INCA033989; Ruxolitinib
- Enrollment: 290
- Primary outcome: Number of participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Number of participants with Treatment-emergent Adverse Events (TEAEs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06034002